Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease

Next Previous
Search
Trial Profile

Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Anastrozole; Capecitabine; Fulvestrant; Letrozole; Luteinising hormone modulators; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Cancer metastases; Liver metastases
  • Focus Therapeutic Use
  • Acronyms AMBRE

    • Most Recent Events

    • 13 Sep 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
    • 13 Sep 2024 Status changed from recruiting to active, no longer recruiting.
    • 11 May 2022 Planned End Date changed from 1 Jun 2026 to 1 Jun 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top